Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Retained Earnings (2017 - 2025)

KalVista Pharmaceuticals' Retained Earnings history spans 11 years, with the latest figure at -$653.2 million for Q2 2025.

  • On a quarterly basis, Retained Earnings fell 18626.2% to -$653.2 million in Q2 2025 year-over-year; TTM through Apr 2025 was -$653.2 million, a 18626.2% decrease, with the full-year FY2025 number at -$653.2 million, down 18626.2% from a year prior.
  • Retained Earnings hit -$653.2 million in Q2 2025 for KalVista Pharmaceuticals, down from -$2.4 million in the prior quarter.
  • Over the last five years, Retained Earnings for KALV hit a ceiling of -$1.4 million in Q2 2021 and a floor of -$653.2 million in Q2 2025.
  • Historically, Retained Earnings has averaged -$111.3 million across 4 years, with a median of -$3.1 million in 2023.
  • Biggest five-year swings in Retained Earnings: skyrocketed 99.32% in 2024 and later crashed 18626.2% in 2025.
  • Tracing KALV's Retained Earnings over 4 years: stood at -$1.4 million in 2021, then crashed by 27553.63% to -$396.0 million in 2023, then soared by 99.39% to -$2.4 million in 2024, then plummeted by 26912.82% to -$653.2 million in 2025.
  • Business Quant data shows Retained Earnings for KALV at -$653.2 million in Q2 2025, -$2.4 million in Q4 2024, and -$2.7 million in Q4 2024.